Further studies showed that an ARV-771 treatment could reduce the leukemia burden to a greater extent and further improve the survival of NSG mice transplanted with the HEL92.1.7 cell line when they are compared with the BET inhibitor OXT015 [54]. This evidence concerns the gene DNER and leukemia.